| |
How is your lab navigating complex NGS workflows? In this webinar, hear subject matter experts explore how a lab informatics solution with out-of-the-box NGS capabilities delivers real value. View Now. 
|
|
Today’s Big NewsSep 15, 2023 |
| By James Waldron Anyone wanting to end the week on a hopeful note could do worse than to check out the duo of biotech IPOs that made it over the line. RayzeBio has just revealed it overshot expectations by raising $311 million, while Neumora Therapeutics was squarely on target with a $250 million offering. |
|
|
|
| Virtual Event |  |
|
|
By Max Bayer As the TIGIT class gets closer to possible clinical success, Bristol Myers Squibb is trimming one of its candidates. |
By Nick Paul Taylor MAPS Public Benefit Corporation has shown off phase 3 data it hopes will secure a landmark approval for MDMA in the U.S. next year. The second phase 3 success is the result of almost 40 years of work to show that psychedelics can treat post-traumatic stress disorder (PTSD) when used to enhance therapy. |
Sponsored by IQVIA With IQVIA’s clinical trial solutions and flexible site support strategies, decentralized trial elementss are being leveraged to enhance patient- centered care as well as support sites through hands- on enablement and implementation of DCT platforms these services. |
By Nick Paul Taylor The FDA has provided yet another twist in the Iovance Biotherapeutics saga. After years of delays, the biotech was on track to receive an approval decision on its tumor-infiltrating lymphocyte melanoma therapy this year only for the FDA to delay the deadline because of “resource constraints.” |
By Helen Floersh CAR-T cell therapy pioneer Carl June, M.D., and scientists from Vertex Pharmaceuticals are among the life sciences winners of 2024 Breakthrough Prizes, awards established by a group of influential tech titans as a means to recognize major achievements in basic science research. |
By Gabrielle Masson,Max Bayer Bill Sibold has left Sanofi after a 12-year run, departing for Madrigal Pharmaceuticals, where he is taking the top spot. |
By Helen Floersh Scientists from leading research institutions called for standardized practices, greater public transparency and more in a new report on gain-of-function research, which comes as the White House deliberates a new framework for how such studies are regulated. |
By Ben Adams Sanofi tapped tech and GSK took out the scissors during their rebrands, but Johnson & Johnson is changing up its iconic logo and name for the “next chapter” in its corporate story. |
By Andrea Park A new day has dawned for AWAK Technologies, the maker of a kidney dialysis machine so small that it can fit in a shoulder bag for on-the-go treatments. |
By Dave Muoio The total could grow by nearly 20,000 more as other unions tally their votes. The large nonprofit would need to reach a contract deal by Sept. 30 to avoid the walk-off. |
By Nick Paul Taylor Amgen and AstraZeneca are returning to the TV party to show how Tezspire can help punks with a lust for life rise above their asthma symptoms and take complete control of their lives. |
By Conor Hale Developed by the South Korea-based company Lunit, the Insight MMG program has previously collected green lights for use in the U.S. and Europe. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
